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The development of genetically engineered models (GEM) of epithelial ovarian cancer (EOC) has been very
successful, with well validated models representing high grade and low grade serous adenocarcinomas and
endometrioid carcinoma (EC). Most of these models were developed using technologies intended to target the
ovarian surface epithelium (OSE), the cell type long believed to be the origin of EOC. More recent evidence has
highlighted what is likely a more prevalent role of the secretory cell of the fallopian tube in the ontogeny of EOC,
however none of the GEM of EOC have demonstrated successful targeting of this important cell type.
The precise technologies exploited to develop the existing GEM of EOC are varied and carry with them advantages
and disadvantages. The use of tissue specific promoters to model disease has been very successful, but the lack of
any truly specific OSE or oviductal secretory cell promoters makes the outcomes of these models quite
unpredictable. Effecting genetic change by the administration of adenoviral vectors expressing Cre recombinase
may alleviate the perceived need for tissue specific promoters, however the efficiencies of infection of different cell
types is subject to numerous biological parameters that may lead to preferential targeting of certain cell
populations.
One important future avenue of GEM of EOC is the evaluation of the role of genetic modifiers. We have found that
genetic background can lead to contrasting phenotypes in one model of ovarian cancer, and data from other
laboratories have also hinted that the exact genetic background of the model may influence the resulting
phenotype. The different genetic backgrounds may modify the biology of the tumors in a manner that will be
relevant to human disease, but they may also be modifying parameters which impact the response of the host to
the technologies employed to develop the model.
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Introduction
Recently a number of insightful reviews have summar-
ized GEM of EOC [1-9]. This review will first briefly
examine current hypotheses on the cell(s) of origin of
human EOC, as this is the cornerstone for the develop-
ment of GEM of EOC. Secondly, the numerous models
of ovarian cancer will be briefly discussed in the context
of the technological approaches exploited for model de-
velopment. Importantly, the advantages, disadvantages
and inherent assumptions implicit in these technologies
will be discussed. Finally, we have found that the genetic* Correspondence: bvanderhyden@ohri.ca
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reproduction in any medium, provided the orbackground can impart dramatic changes in the pheno-
type of disease in a GEM of EOC and the latter part of
this review will discuss the relevance of genetic back-
ground and inbred strains to future model development.
The fundamental premise in the design of GEM of
EOC is the development of tools or strategies to target
genetic change to the presumed precursors of the dis-
ease. Traditionally, the origin of human EOC was pre-
sumed to be in the OSE, or in the epithelial lining of
inclusion cysts that had arisen from the OSE and the
evidence supporting this has been extensively reviewed
[10-14]. The OSE retains the potential to undergo Mül-
lerian differentiation as evidenced by the expression of
Müllerian markers in naturally forming inclusion cysts,
in inclusion cysts arising at increased frequencies in
mice harboring specific genetic lesions [15,16] and inLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Garson et al. Journal of Ovarian Research 2012, 5:39 Page 2 of 11
http://www.ovarianresearch.com/content/5/1/39OSE coaxed into different Müllerian lineages following
the introduction of specific Hoxa genes [17].
Recently, growing evidence has challenged this theory
and identified the secretory cell of the distal fallopian
tube as a putative EOC precursor [18-25]. While evi-
dence favors a fallopian tube origin for a high proportion
of high grade serous ovarian adenocarcinomas, there has
not been sufficient evidence to rule out a parallel role
for the OSE [25,26].
Finally, it must be kept in mind that evidence of early
precursors of EOC in the OSE or the secretory cell of
the distal fallopian tube implicates not only these differ-
entiated cell types as potential origins of the disease, but
it also implicates putative progenitor or tissue stem cells
as well [27-32].
Targeting the mouse for models of ovarian cancer
Direct expression of a transgene from a tissue specific
promoter
In the absence of a promoter candidate specific for OSE,
Connolly et al. [33] found that the Amhr2 (also known
as MISIIR) promoter was transcriptionally active in mur-
ine OSE in addition to reported expression in granulosa
cells [34] and the stroma of the Müllerian duct [35]. In
the first GEM of EOC, female mice expressing the SV40
early region (SV40TAg) from the Amhr2 promoter
developed poorly differentiated serous tumors derived
from the OSE. Interestingly, granulosa cell tumors did
not arise in this model, despite the potential for the
Amhr2 promoter to drive expression in granulosa cellsd
a
c
Figure 1 Expression of TAg and PAX8. TAg in the oviductal epithelium
SV40TAg)1Bcv mice as shown by immunohistochemistry. PAX8 expression
of a tumor from an ovariectomized FVB/n-Tg(Amhr2-SV40TAg)1Bcv mouse[34,35] and the potential for granulosa cells to become
malignantly transformed by the SV40 early region
[36,37] or the SV40 large T antigen (TAg) [38].
In our laboratory, we noted in an independent
Amhr2-SV40TAg transgenic line (Tg(Amhr2-SV40TAg)
1Bcv) generated on the FVB/n straina, that in addition
to evident TAg expression in the ovary, expression was
also seen in the epithelium and stroma of the oviduct
(Figure 1a) and in the epithelium of the uterus
(Figure 1b). Expression of TAg in the uterine and ovi-
ductal epithelium was not expected from the endogen-
ous Amhr2 promoter and may result from altered
regulation of the ectopic promoter fragment. In order to
examine potential tumorigenesis from the oviduct and
uterus, ovaries were removed from mice 7–8 weeks of
age. Tumors arising from the remaining reproductive
tract were slower to develop and showed significantly
more cells expressing PAX8 than tumors developing
from the ovaries of the non-ovariectomized controls. Ex-
pression of PAX8, a marker of oviductal and uterine epi-
thelium (Figure 1c, 1d, respectively), in tumors from
ovariectomized mice may indicate their origin in the ovi-
ductal or uterine epithelium. Interestingly, several
regions of papillary differentiation were found in tumors
with PAX8 positivity (Figure 1e).
Direct targeting of SV40TAg expression to the ovi-
ductal secretory cells was attempted using the oviduct-
specific glycoprotein (Ovgp1) promoter [39]. Although
oviductal tumors were reported they were not well char-
acterized [39]. All mice developed uterine tumors ande
b
and stroma (a) and in the uterine epithelium (b) of FVB/n-Tg(Amhr2-
in the normal oviduct (c), uterine epithelium (d) and papillary lesions
(e). Scale bars represent 50 μM.
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documented OVGP1 expression [40,41].
Other relevant models have induced premalignant
changes, but not cancers, in the OSE and have impli-
cated various signaling pathways in these changes. Ex-
pression of a constitutively active PIK3CA by the Amhr2
promoter led to OSE hyperplasia [42]; the expression of
dnSMAD2 from the Amh promoter gave rise to ovarian
inclusion cysts with Müllerian differentiation [43] and
OSE in mice heterozygous for disabled-2 demonstrated
surface dysplasia and papillomatosis [44].
While the direct transgene approach led to the first
model of EOC, the implementation of such strategies
remains unpredictable. Both the Amh and Amhr2 pro-
moters express in both granulosa cells and OSE [33,43],
yet their use to express the SV40TAg has led to granu-
losa cell tumors [38] and epithelial tumors [33], respect-
ively. It is possible that there are subtle differences not
only in the static expression from a promoter at a fixed
time point, but also differences in the developmental
timing of expression that might be critical for the
phenotype of the model. It must not be forgotten that
the expression of oncogenes in the earliest cell types that
initiate promoter function may also alter the develop-
ment of subsequent lineages of cells. This is in contrast
to our notions of tumorigenesis, where dominant genetic
changes occur stochastically in cells residing in organ-
isms that for the most part have completed their devel-
opmental programs.
Cre-lox conditional targeting: Tissue expression of Cre
The first model exploiting the tissue-specific expression
of Cre recombinase used the Fshr promoter to inactivate
loxP-flanked (floxed) Brca1 alleles in granulosa cells,
however serous cystadenomas carrying unrecombined
Brca1 developed in the OSE [45]. Increased expression
of aromatase [46], and alterations of the estrus cycle [47]
due to the inactivation of Brca1 may have collectively
led to increased levels of estrogen [47] contributing to
the observed changes in the OSE. While this model may
seem unique, other examples in the female reproductive
tract of genetic change in one compartment leading to
hyperplasia or tumorigenesis in a second compartment
have been reported recently [48,49].
The Amhr2 promoter, used for the first GEM of EOC,
has been exploited for the expression of Cre in a number
of models. Expression of Cre from the endogenous
Amhr2 promoter leads to conditional expression of LacZ
in the Gtrosa26tm1Sor reporter mice as early as embry-
onic day 11.5 in female urogenital ridges, and in the fe-
male gonads and Müllerian ducts at embryonic day 12.5.
In the adult mouse, expression of LacZ has been noted
in the granulosa cells of follicles (not primary or primor-
dial), thecal cells, corpus luteum, OSE and stromal cellsof the oviduct and uterus [50]. Importantly, LacZ ex-
pression has not been reported in the oviductal or uter-
ine epithelium.
The first low grade EOC model was reported by Fan
et al. in 2009 [51]. Briefly, while examining the role of
KRASG12D and PTEN signaling in granulosa cell devel-
opment, they noted in triple transgenic mice (Ptenfl/fl;
KrasG12D;Amhr2-Cre) that the loss of Pten and gain of
KrasG12D in the OSE led to the development of low
grade serous adenocarcinomas. Activation of KrasG12D
alone by Amhr2-Cre did not lead to tumorigenesis, but
rather growth arrest of granulosa cells and OSE hyper-
plasia [52]. Conditional loss of Pten alone in Amhr2-Cre
mice resulted in alterations in granulosa [53,54] and
uterine myometrial cells [55] but not OSE.
The OSE have also been targeted for alteration of the
WNT pathway through the activation of β-catenin fol-
lowing the conditional deletion of exon 3 (Ctnnb1Δex3)
in Amhr2-Cre mice [56]. While all mice developed pre-
tumoral nests of cells at the ovarian surface, 50% of mice
progressed to develop EC. Combining the conditional
activation of Ctnnb1Δex3 with the conditional inactiva-
tion of Pten led to all mice developing EC. The pheno-
type of this model is in contrast with other reports that
described the development of granulosa cell tumors in
mice with conditional loss of Pten and conditional acti-
vation of β-catenin (Ctnnb1Δex3) induced either in the
Amhr2-Cre line or through granulosa specific expression
of Cre in the Cyp19Cre (Tg(CYP19A1-cre)1jri) line [57].
It is unclear from the reports [53,56,57] whether the dis-
crepancies relate to different interpretations of the
pathological findings or whether possible differences in
the breeding strategies to achieve the triple transgenic
model animals led to different genetic backgrounds and
outcomes.
The third transgenic model of EOC generated using
the Amhr2-Cre transgenic strain was achieved through
the conditional inactivation of Dicer and Pten, two genes
frequently down-regulated in ovarian cancer [58]. While
the phenotype of Amhr2-Cre mediated deletion of Pten
is described above, the conditional deletion of Dicer
alone resulted in smaller oviducts and uterine horns, a
disorganized oviduct, changes in the glandular structure
of the uterus [59] and alteration of ovarian follicle pools
[60]. The combined conditional inactivation of both
Dicer and Pten led to the development of high grade ser-
ous adenocarcinomas from the oviduct.
In contrast to evidence suggesting an origin for human
ovarian cancer in the epithelium of the fallopian tube,
Kim et al. identified early lesions in the stroma of the
oviduct, consistent with the expression pattern from the
Amhr2 promoter in this tissue [58]. These lesions and
the resulting tumors expressed epithelial markers with
gene expression patterns which aligned with human high
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these early stromal lesions to the presumed fallopian
tube secretory cell precursors of human disease is not
clear. In the mouse, oviductal epithelial cells are not
derived from stromal cells which express AMHR2 [61].
It would be of interest to determine if rare epithelial
cells reside in the stroma of wild type mice or whether
the loss of tumor suppressors in the oviductal mesen-
chyme leads to the ectopic development of epithelial
precursors.
In summary, the targeting of genetic change through
the inactivation of tumor suppressors (Brca1, Pten,
Dicer) or the activation of oncogenes (KrasG12D, CtnnB1)
using the tissue specific expression of Cre recombinase
has led to EOC models encompassing benign tumors,
EC, low grade serous and high grade serous disease, how-
ever, there remain a number of caveats. First, the transi-
ent expression of Cre from a tissue specific promoter will
mark that cell and all subsequent lineages with the
designed genetic change, irrespective of whether the
promoter driving Cre has ceased to be transcriptionally
active. This may exacerbate concerns about the loss of
tumor suppressors or gain of oncogenes leading to
models of “developmental cancer”.
A second caveat of knock-in strains expressing Cre re-
combinase is dependent on the design. Transgenic lines
such as the Amhr2-Cre line, which create a null allele
[50], are used experimentally as heterozygotes. While no
reports indicate any possible phenotypic consequences
of haploinsufficiency of the Amhr2 gene, it remains a
theoretical possibility that this may shape the phenotype
of the resulting models. A phenotype based on haploin-
sufficiency was reported for Foxg1-cre mice [62] in
which altered cell populations and tissue structure were
observed in the brain of heterozygous mice. Further
seemingly innocuous facets of the experiment can also
lead to surprising phenotypic consequences. Mice carry-
ing unrecombined floxed alleles can manifest pheno-
types distinct from the wild type [63,64], and strains of
mice expressing Cre from tissue specific promoters can
present altered phenotypes in the absence of any floxed
target genes [65].
Cre-lox conditional targeting: Viral expression of Cre
Adenoviral vectors expressing Cre recombinase (Ad-
CMV-Cre) have been used for GEM of EOC to control
both the time and location of Cre expression. Injection
of virus through the bursal membrane or infundibulum
has been used primarily to alter gene expression in the
OSE, however this route also permits exposure of the
bursal membrane and the oviductal epithelium to admi-
nistered virus. The accessibility of the oviductal epithe-
lium to introduced virus can clearly be seen in
Figure 1c, which shows the externalized epithelium ofthe oviductal infundibulum, with secretory cells (PAX8
expressing) within 30 μM of the OSE.
The first model of EOC using the intrabursal adminis-
tration of Ad-CMV-Cre reported high grade serous ovar-
ian adenocarcinomas in mice that had conditional loss
of Trp53 and Rb1 alleles following Cre-mediated recom-
bination [66]. Interestingly, subtle variations in method-
ology may impact the phenotypes of this model, as
different results have been noted in different laborator-
ies. Clark-Knowles et al. found the loss of Trp53 and
Rb1 alleles using intrabursal administration of Ad-CMV-
Cre led to the development of leiomyosarcomas, a
phenotype that was also seen with 100% penetrance in
mice with conditional deletion of Trp53 alleles alone
[67]. In contrast, Flesken-Nikitin only observed the rare
appearance of serous adenocarcinomas in Trp53loxP/loxP
mice treated with Ad-CMV-Cre [66]. A third report by
Quinn et al. observed the rare occurrence of leiomyosar-
comas in mice with conditional loss of Trp53. Possible
differences in methodology, including different mouse
genetic backgrounds, may have caused the variable out-
come of these experiments. Novel in the experiments of
Quinn et al. and Clark-Knowles et al. was a more aggres-
sive or more penetrant disease when Brca1 was deleted
in addition to loss of Trp53 [67,68], a finding also noted
for uterine leiomyosarcomas [69].
Clark-Knowles et al. (2009) speculated that one pos-
sible source of the leiomyosarcomas was from the
smooth muscle cells of the bursal membrane. Recently,
Szabova et al. [70] re-examined the role of Rb1, Trp53,
Brca1 and Brca2 in EOC applying several new innova-
tions that addressed two concerns. First, the concern
that deletion of Rb1 alone may be ineffective due to
functional compensation by p107 or p130 [71] led the
authors to abrogate Rb1, p107 and p130 function
through the Cre-dependent conditional expression of a
deletion mutant of the SV40 Large T antigen, T121 [72].
T121 binds and inactivates RB1 and related proteins
p107 and p130 [72,73] but does not inactivate TRP53.
Furthermore, to eliminate the potential transformation
of smooth muscle cells in the bursal membrane, condi-
tional expression of T121 was from the cytokeratin 18
promoter. In contrast to the previous reports [66,67], in-
activation of RB1 (and p107, p130) following activation
of the T121 led to a range of abnormalities in the OSE in-
cluding serous EOC (often high grade) in 18% of mice.
Single or double loss of Trp53, Brca1 or Brca2 function
failed to generate OSE pathology while loss of p53 alleles
in conjunction with expression of T121 led to both the
increased frequency and progression of high grade ser-
ous EOC [70].
In a related model, intrabursal administration of Ad-
CMV-Cre was used to activate expression of the SV40
early region in mouse OSE [74]. The tumors emerging
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tumors. While the SV40TAg is able to inactivate both
RB1 (and p107, p130) and TRP53, additional roles in
transformation have been described for both the large
and small t antigens [75] and how each of these contrib-
ute to the described phenotype is not known. Interest-
ingly, treatment of mice with 17β-estradiol led to an
earlier onset of tumors, decreased survival and distinct-
ive papillary histology [74].
While targeting of OSE using the Amhr2-Cre transgenic
to activate KrasG12D and to inactivate Pten resulted in low
grade serous adenocarcinomas [51], similar activation/
inactivation of these genes induced following the intra-
bursal injection of Ad-CMV-Cre led to the development
of ovarian endometrioid adenocarcinomas [76]. While
both of these reports indicate tumors arising from the
OSE, the two different strategies may target different
subsets of cells on the ovarian surface. Alternatively,
the different outcomes in these two experiments may
reflect the activation/deletion of these genes at different
times in development. Inactivation of Pten alone follow-
ing the intrabursal administration of Ad-CMV-Cre has
been reported to lead to the development of endome-
trioid lesions [76] or serous papillary hyperplasia [77],
again a variable outcome depending on the reporting
laboratory.
Activation of KrasG12D has also been evaluated in con-
junction with the conditional loss of the Trp53 allele fol-
lowing intrabursal delivery of Ad-CMV-Cre [78]. While
the resulting tumors were described as sarcomatoid
ovarian carcinomas, the authors illustrated the utility of
a more stochastic model of tumor initiation for under-
standing the evolution of immune cell infiltrates in the
tumor microenvironment. Importantly, the authors
reported that tumor growth is controlled initially by im-
mune surveillance and the emergence of clinically sig-
nificant tumors results from the development of an
immunosuppressive tumor microenvironment.
Other investigators have addressed the loss of Pten in
conjunction with further insult to the Akt pathway [79].
Interestingly, while one of the primary interests in the
inactivation of Pten is to activate the Akt pathway,
Kinross et al. inactivated Pten and activated a constitu-
tively active mutant Pik3ca allele (Pik3ca*) expressed
from the Pik3ca endogenous promoter. While the single
lesions alone led to serous papillary hyperplasia, the
combined loss of Pten and expression of Pik3ca* led to
the development of high grade serous ovarian cancer.
Loss of PTEN function has also been coordinated with
activation of the Wnt signaling pathway [80,81]. Wu
et al. reported a statistical association of Pten mutations
with Wnt pathway defects in ovarian endometrioid
adenocarcinomas in clinical samples and used Ad-CMV-
Cre to activate the Wnt pathway by deletion of Apc andthe Akt pathway by deletion of Pten to give rise to ovar-
ian endometrioid adenocarcinomas in 100% of mice.
Interestingly, activation of the Akt and Wnt signaling
pathways was also reported using Amhr2-Cre to inacti-
vate Pten and activate the expression of a dominant
stable β-catenin [53,56], however depending on the
reporting laboratory, the mice either developed EC [56]
in agreement with Wu et al. or granulosa cell tumors
[53].
In summary, the administration of Ad-CMV-Cre intra-
bursally has led to models of both high grade serous and
endometrioid adenocarcinomas. While Ad-CMV-Cre
models require surgical intervention to initiate the
tumorigenic process, the sudden induction of genetic
mutation in the target cells in the adult is more relevant
to the human disease than a developmentally regulated
acquisition of genetic change. The exposure of the ovar-
ian surface, bursal membrane, oviduct and in some
instances granulosa cells [77] to intrabursally injected
adenovirus represents a simple model of delivery of Cre,
however the efficient infection of polarized epithelium of
the oviduct and even polarized OSE [82] is much more
complicated.
The successful targeting of a cell for expression of
Cre recombinase from Ad-CMV-Cre vectors depends
on the activity of the CMV promoter in that cell type
and the level of expression of the virus receptor and co-
receptors, CAR [83] and the αvβ3 or αvβ5 integrins [84],
respectively. In polarized epithelium, infection can be
restricted to the basolateral surface of the cell due to the
absence of apically expressed CAR [85,86]. A number of
factors can sensitize cells to apical infection, including
the apical expression of alternate isoforms of CAR [87],
and the expression of extrinsic factors such as CXCL8
[88] or lactoferrin [89]. Expression of both CXCL8
[90,91] and lactoferrin [92,93] has been reported in fol-
licular fluid and within the fallopian tube. While suc-
cessful infection of OSE is evident in the reported
models, it cannot be assumed that all cells are equally
sensitive to infection.
Previously, we have examined infection of the OSE
following the intrabursal administration of varying
titres of Ad-CMV-/acZ. Although infection, measured
by LacZ expression, was at times found throughout
the entire ovarian surface, a subset of mice showed in-
fection localized frequently at the apex of what appear
to be corpora luteal structures (Figure 2). The reasons
for such localized LacZ expression on the epithelial
surface are not clear, but it could result from a num-
ber of mechanisms, including the selective expression
of LacZ from the CMV promoter resident in the
adenoviral vector or the selective infection of cells on
the ovarian surface that had lost polarity during ovulatory
wound repair.
Figure 2 LacZ expression in Ad-CMV-lacZ treated ovaries. Intrabursal administration of 107 (left panel) or 108 (right panel) plaque forming
units (pfu) of Ad-CMV-lacZ. Administration of 107 pfu results in a selective infection of a subset of cells on the surface of the murine ovary (left).
Ovaries were fixed and stained with X-gal to detect expression of β-galactosidase. The scale bar on the left panel indicates approximately
150 μM.
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have indicated that adenovirus can infect the epithelium
of the ovary, oviduct and uterus [94], it remains a con-
cern that subsets of cells may have varied sensitivities to




Figure 3 Effect of genetic strain on ovarian tumors in Tg(Amhr2-SV40
FVB/n-Tg(Amhr2-SV40TAg)1Bcv (a) are localized to distinct regions of the tu
throughout the entire ovarian stroma as early as embryonic day 18 (b) with
days of age. Expression of TAg in the F1 ovaries from a cross of the FVB/n-
weeks of age and then only localized to the ovarian cortex as shown (c, da
enlarged area).Genetic background
The importance of mouse strain on the investigation of
transgenic models of cancer has been recently reviewed
[95]. Our laboratory found striking phenotypic differ-
ences in a transgenic line, Tg(Amhr2-SV40TAg)1Bcv, de-
pending on whether it was in a pure FVB/n or a mixedd36 d61
CK19 α-inhibin 
TAg)1Bcv mice. Cytokeratin 19 (CK19) and α-inhibin expression in the
mor that appear mutually exclusive. TAg expression is found
exclusion of expression from large follicles apparent at 36 and 61
Tg(Amhr2-SV40TAg)1Bcv to C57Bl/6 mice is apparent after several
y 43). Scale bars indicate 100 μM (a), 500 μM (b + c) or 100 μM (c,
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arising in Tg(Amhr2-SV40TAg)1Bcv and independent
FVB/n transgenic founders showed regional expression
of both cytokeratin and α-inhibin that tended to be mu-
tually exclusive (Figure 3a). In the FVB/n line, stromal
hyperplasia of TAg expressing cells is evident as early as
embryonic day 18 (Figure 3b). In contrast , F1 progeny
of a backcross into the C57/Bl6 strain revealed TAg
expressing lesions only in the cortex of the ovary near
the ovarian surface as late as 6 weeks of age (Figure 3c),
a phenotype which is distinct from that observed in the
pure FVB/n background. Finally, the delayed initiation
of ovarian cancer in the FVBB6F1 mice was reflected in
a longer mean time to endpoint of 21 weeks compared
to 15 weeks observed for the Tg(Amhr2-SV40TAg)1Bcv
in the pure FVB/n background.
A number of the EOC models described in this review
have targeted similar pathways with different conse-
quences. The modeling of Trp53 and Rb1 loss following
the intrabursal delivery of Ad-CMV-Cre was performed
by two laboratories with different outcomes [66,67]. The
penetrance and phenotype of tumors arising in Ad-
CMV-Cre treated animals with only loss of Trp53 was
also varied between reports [66-68]. While these groups











































Figure 4 GEM of EOC. Outline of current models of EOC originating from
oviductal stroma (top left). Phenotypes of OSE carrying single genetic lesio
oncogenes using the Amhr2 promoter (gray arrows), or expression of Cre fr
endogenous Amhr2 promoter (green arrows) are indicated. Murine models
(HGSC), low grade serous ovarian cancer (LGSC), endometrioid ovarian can
Penetrance of the noted phenotypes, when less than 80%, is expressed as
Phenotypes of models are presented in yellow backgrounds, however mod
separate means (eg. Ad-CMV-Cre versus Amhr2-Cre) are shaded with the samet al. reported the backcross of their strains to the FVB/n
background. Although not verified, the varied pheno-
types in these studies may be a consequence of different
genetic backgrounds.
One future goal for the continued development of
GEM of EOC is to identify modifiers of the disease
through crosses with genetically varied strains of mice.
While libraries of recombinant inbred strains have been
developed for this purpose [96], the requirement of
many of the EOC models for three transgenes and a re-
quirement for homozygosity of floxed tumor suppressor
alleles makes the breeding for such a systematic ap-
proach challenging. In addition, the use of GEM of EOC
to screen for genetic modifiers of disease that are rele-
vant to human will require sorting through “noise”
which is related to genetic modifiers of “technology” as
opposed to modifiers of the disease. For example, strain
differences may modulate parameters that influence the
efficiency of viral infection, or subtly modify temporal
patterns of promoter function.
Conclusions
This review has examined some of the technological
parameters that have shaped the existing GEM of EOC.





























































genetic modification of OSE (centre), granulosa cells (bottom left) and
ns induced by Ad-CMV-Cre (red arrows) or tissue specific expression of
om the FSHR promoter (blue arrow) or expression of Cre from the
elicited phenotypes consistent with high grade serous ovarian cancer
cer (EC), leiomyosarcomas (LMS), or the indicated phenotypes.
the percentage of animals affected and displayed in brackets.
els based on the activation/inactivation of similar pathways by
e colors to facilitate comparison.
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adenocarcinoma [33,58,66,70,79], low grade serous
adenocarcinoma [51], and endometrioid carcinoma
[56,76,80] (Figure 4). Eight GEM of EOC derived from
OSE adds weight to the notion that the OSE retains a
plasticity that does not preclude malignant transform-
ation into cancers with evident Müllerian differentiation.
The lack of GEM of EOC representing cancers arising
primarily from the oviductal epithelium may be a conse-
quence of inefficient targeting strategies.
Overall, the development of GEM of human cancers is
a balance between convenience and authenticity. By
some measures, the ultimate GEM of EOC would be a
transgenic model requiring no intervention yet yielding
100% penetrance in mature animals of a phenocopy of
the human disease with a predictable onset and highly
consistent endpoint. While useful for statistical analysis
of survival in therapeutic trials, this type of model is in
stark contrast to the human disease which arises sto-
chastically, in varied genetic backgrounds with highly
variable rates of progression.
Now that some excellent models of EOC have been
derived, it is time to develop models that may be less
predictable, yet designed with imaging in mind such that
100% penetrance and highly defined endpoints are not
essential. Consistent with the development of more sto-
chastic models of ovarian cancer, GEM which exhibit
genomic instability [68,97], a prominent feature of high
grade serous EOC, should be important for future model
development. Importantly, rather than modelling the de-
velopmental emergence of tumors through the expres-
sion of oncogenes or deletion of functional tumor
suppressors using developmentally regulated promoters,
inducible systems targeting the oviductal epithelium and
OSE are needed such that genetic changes can be intro-
duced more stochastically without the requirement for
surgical intervention. The initiation of tumorigenesis in
the adult mouse would not only better reflect the origin
of ovarian cancer in women, but it also offers a more
relevant examination of the interplay of the immune sys-
tem with emerging tumors [78]. In addition, controlled
timing of tumorigenesis in the adult mouse would allow
some flexibility in studying the disease as a function of
age, including manipulation of the hormonal status of
the mice either through hormonal supplementation [74]
or induction of menopause [98]. This would provide an
enhanced relevance of GEM of EOC, but the challenges
remain on how to effectively target the appropriate cells
using available technologies.Endnotes
a All animal experiments described in this study were
performed according to the Guide to the Care and Useof Experimental Animals established by the Canadian
Council on Animal Care.
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